Press Release
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
–News Direct–
Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, has been attracting substantial interest from investors looking for opportunities in the biotech sector.
CRDL is currently developing CardiolRx and CRD-38 therapies for heart diseases, including recurrent pericarditis, acute myocarditis, and heart failure.
Over the past year, CRDL stock has surged by more than 250%, illustrating the increasing level of investor interest in the company. The stock now trades around $2.35 per share and appears to be on track to test its next potential resistance at $3.
For investors who may be wondering whether they missed out on Cardiol Therapeutics' (NASDAQ:CRDL) (TSX:CRDL) impressive rally, heres some good news. The stock has the potential for further upside considering the fact that Cardiol will release topline data for its Phase 2 MAvERIC-Pilot clinical trial evaluating the efficacy of CardiolRx for the treatment of recurrent pericarditis sometime in early June, which, if positive, has the potential to send the stock higher.
Moreover, several analysts have reiterated that the stock has the potential for significant upside, further reaffirming Cardiols growth prospects.
For instance, Joe Gantoss of Chimera Research Group says he wont be surprised to see Cardiols price break past the 3-year high at $4.96 if the recurrent pericarditis data show a clear success and open the path to move to the next stage with Phase 3 trial.
According to Gantoss, Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has many things going in its favor right now heading into a critical Phase 2 trial readout in recurrent pericarditis in June that he believes will lead to a positive outcome.
Those include a strong rationale for its mechanism of action as well as receipt of FDA Orphan Drug Designation (ODD), which suggests a positive signal in an early data subset, plus a tried-and-true recurrent pericarditis trial design with experienced investigators at the helm.
Thanks to the FDA ODD grant, CardiolRx has a clear path to expedite the development timeline and will ensure a market exclusivity period of at least 7 years. And the great thing is that theres a robust market for innovation in this indication, as evidenced by a successful recent drug launch.
At a current market cap of $162 million, this is clearly underappreciated and unrecognized by the market at the present time. For reference, company peer Kiniksa Pharmaceuticals (KNSA) now has a $1.4 billion market cap on expected sales of $360-$380 million for treating recurrent pericarditis, with single to low double-digit market penetration. We also note the example of Jazz Pharmaceuticals (JAZZ) buying out company peer GW Pharma (GWPH) for approximately $7 billion after Epidiolex, a formulation sharing a similar active ingredient with CardiolRx, reached half a billion in sales in epilepsy over 2 years (now guiding for a US $1-billion-dollar franchise in the years to come).
Clearly, a $160 million market cap does not do Cardiol justice. With positive data in Q2, the path to market becomes a slam dunk, and the stock should surge to the upside in response, says Gantoss.
In addition, analyst Vernon Bernardino of H.C. Wainwright & Co reiterated their Buy rating and issued a $9 price target, which implies that Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a potential upside of about 300% from current levels.
There is currently only one FDA-approved therapy for recurrent pericarditis. With CardiolRxs strong safety profile vs. anti-inflammatory and immunosuppressive drugs, the analyst believes CardiolRx has the potential to be a safe, new approach to recurrent pericarditis treatment and is underappreciated. Likewise, Bernardino also expects topline results from MAvERIC-Pilot to be a positive catalyst in early June.
ARCHER is Cardiols Phase 2 multi-center, international, double-blind, randomized, placebo-controlled trial investigating the safety, tolerability, and impact of CardiolRx on myocardial recovery in patients presenting with acute myocarditis. ARCHER trial design, rationale, and blinded baseline data on the first 50 patients randomized were the subject of an oral presentation at the World Congress on Acute Heart Failure earlier this month.
According to Bernardino, they are positive about the results as they look for ARCHER to assist in furthering understanding of the therapeutic potential of CardiolRx and complement the MAvERIC-Pilot Phase 2 study.
ARCHER patient recruitment has been accelerating, with the trial expected to enroll 100 patients in the United States, Canada, France, Brazil, and Israel. In fact, ARCHER has now exceeded 85% of target enrollment, and as a result, H.C. Wainwright & Co. believes prospects for its completion by early 2025 are good.
Huge unmet medical need
Pericarditis is a heart disorder consisting of inflammation of the pericardium, the membrane or sac that surrounds the heart and protects it from damage during contraction. Acute pericarditis lasts about 4-6 weeks before resolving, but often patients can experience a second episode. If another episode occurs following a period of 4-6 weeks without symptoms, this is considered recurrent pericarditis.
At the moment, the first-line conventional treatment for recurrent pericarditis is NSAIDs or aspirin, with or without colchicine. For the second-line therapy, for patients with continued recurrence and inadequate response, corticosteroids are administered despite safety issues and difficulty tapering or discontinuation.
The only FDA-approved therapy, ARCALYST (rilonacept) averages over $150,000 per year and is primarily used for over three recurrences.
The most common complication of pericarditis is recurrence, occurring in 15-30% of first-time pericarditis cases, some complications can be deadly, and an estimated 5% of all hospitalizations for chest pain in the US and Europe are due to pericarditis.
In the US, the annual prevalence is about 160,000 cases (based on 40/100,000) which includes 38,000 cases with a recurrence. Hospitalization costs average $20 $30k with a 6 8-day length of stay.
So far, ARCALYST has had impressive results in recurrent pericarditis and strong market uptake since its launch in 2021, and this is bullish for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) since it reflects a market in need of innovation and ready to embrace new alternatives.
Takeaway
In summary, the near-term pericarditis clinical proof-of-concept data expected in early June could be a major catalyst and turning point for Cardiol and its valuation. Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a strong financial position, being debt-free and is well-capitalized to achieve corporate milestones into 2026, which is why analysts remain confident in the companys long-term growth prospects.
Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cardiol Therapeutics to assist in the production and distribution of content related to CRDL. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.
Contact Details
RazorPitch Inc
Mark McKelvie
+1 585-301-7700
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/analysts-consensus-reaffirms-significant-upside-potential-for-cardiol-therapeutics-675722872
RazorPitch CRDL
COMTEX_452999953/2655/2024-05-28T07:05:27
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
AIA Labs, a trailblazer in blockchain innovation, has officially launched AIA Chain, a next-generation blockchain platform designed specifically for high-performance financial transactions. Fully compatible with the Ethereum Virtual Machine (EVM), AIA Chain integrates cutting-edge technology with unparalleled speed, scalability, and cost-efficiency, making it a leader in decentralized finance (DeFi), blockchain payments, and Web3 infrastructure.
Why AIA Chain Stands Out in the Crypto Ecosystem
AIA Chain is setting new benchmarks in the crypto and blockchain industries, addressing key challenges such as transaction speed, scalability, cost-efficiency, and regulatory compliance. Its unique features make it a compelling choice for developers, institutions, and users seeking innovative solutions in the rapidly evolving world of blockchain technology, cryptocurrencies, and smart contracts.
With the global digital payments market projected to reach $20 trillion by 2030, AIA Chain is strategically positioned to become a cornerstone of blockchain-based payment infrastructure.
Unrivaled Transaction Speed and Low Fees
AIA Chain is redefining the standards for blockchain payments with:
- Over 100,000 transactions per second (TPS): AIA Chain surpasses the performance of major blockchains like Ethereum, Binance Smart Chain (BSC), and Solana.
- Ultra-low transaction costs: At just $0.0002 per transaction, AIA Chain outperforms many leading blockchains, making it ideal for high-frequency use cases such as crypto payments, remittances, and DeFi protocols.
- Meta-transaction mechanism: AIA introduces this advanced feature to lower the barriers for both developers and users, enhancing usability and adoption.
Built for DeFi, Web3, Gamefi, On-chain AI Agent and Beyond
AIA Chain is fully compatible with Ethereum, enabling seamless migration of projects and smart contracts. This makes it an ideal platform for developers building DeFi apps, NFT marketplaces, metaverse projects, and GameFi ecosystems. The platform’s focus on scalability and interoperability ensures that projects can thrive in a rapidly growing Web3 world.
Key Features of AIA Chain
APoS Consensus Mechanism and ISN Architecture
AIA Chain employs Adaptive Proof of Stake (APoS) and a unique Internet Sharding Network (ISN) architecture. These innovations:
- Prevent centralization and whale manipulation, ensuring a fair and secure network.
- Increase transaction throughput and enhance the platform’s decentralization.
- Drive high network activity, making AIA Chain a dynamic and robust ecosystem.
EVM Compatibility and Developer-Friendly Tools
By being fully compatible with EVM, AIA Chain simplifies project migration from blockchains like Ethereum, Binance Smart Chain, and Polygon. The inclusion of AVM (AIA Virtual Machine) provides developers with advanced tools to build scalable and innovative solutions, enabling smart contract deployment and decentralized application (dApp) development with ease.
Scalability and Layer 2 Solutions
AIA Chain supports Layer 2 scaling solutions and cross-chain interoperability, offering developers the tools to create applications that transcend blockchain silos. These features unlock vast potential for DeFi ecosystems, cross-border crypto payments, and enterprise blockchain solutions.
Focus on Compliance and Institutional Adoption
AIA Chain prioritizes regulatory compliance in global markets, providing a secure and legally compliant environment for both institutional and individual users. This focus positions AIA Chain as a preferred platform for enterprise blockchain adoption, bridging the gap between traditional finance (TradFi) and decentralized finance (DeFi).
Developer and Ecosystem Support
The AIA Foundation actively supports promising projects with funding, technical guidance, global roadshows, and marketing resources. By fostering developer growth, the foundation aims to build a vibrant, innovative ecosystem that accelerates the adoption of blockchain technology and cryptocurrency worldwide.
Transforming the Blockchain Landscape
AIA Chain’s unique combination of speed, affordability, and developer-friendly features positions it as a transformative force in the blockchain industry. Its applications span:
- DeFi Protocols: Supporting decentralized exchanges (DEXs), liquidity mining, and innovative yield farming strategies.
- Crypto Payments: Optimized for real-time, low-cost transactions in retail and institutional markets.
- Gamefi, Ai-Fi, Memecoin, NFT and Web3 Ecosystems: AIA Chain provides a scalable foundation for Gamefi, Ai-Fi, Memecoin, NFTs, metaverse projects, and decentralized governance applications.
- Enterprise Adoption: With a focus on compliance and scalability, AIA Chain bridges the gap between traditional financial systems and blockchain technology.
About AIA Labs
As the operational backbone of AIA Chain, AIA Labs is committed to fostering a dynamic and inclusive blockchain ecosystem. By providing technical leadership, regulatory insights, and developer support, AIA Labs is empowering a new generation of blockchain applications in DeFi, Web3, and beyond.
Support for Developers:
The AIA Foundation, managed by AIA Labs, offers comprehensive support for promising projects, including funding, technical assistance, and global marketing resources. By lowering barriers to entry, AIA Labs accelerates adoption and innovation within the blockchain space.
Focus on Compliance and Stability:
AIA Labs prioritizes compliance with regulatory frameworks across key global markets, establishing AIA Chain as a reliable platform for institutions and individuals alike, providing a compliant and secure platform for institutions and individuals. This commitment to compliance establishes AIA Chain as a preferred choice for financial applications requiring high-frequency transactions and reliability.
For more information, visit AIA Labs Website.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
London, UK, 26th November 2024, ZEX PR WIRE, Tradeview Markets proudly stole the spotlight at the Finance Magnates London Summit 2024, a premier two-day event that brought together the biggest names in the financial industry.
With one of the best-looking booths, Tradeview’s presence was unmatched, attracting more attendees than any other exhibitor at the summit.
A Hub of Connection and Innovation
Tradeview´s team made the most of every moment, engaging with industry leaders, networking with professionals from across the globe, and showcasing cutting-edge technological advancements. Visitors at the booth not only experienced the future of trading but also left with exclusive giveaways—caps, ties, pens, and more—making Tradeview’s stands the ultimate destination at the summit.
Unforgettable Experiences and Star Power
In a highlight that wowed attendees, players from the Leicester Tigers men’s and women’s teams were at booth #31 to meet fans and take photos. This unique collaboration underscored Tradeview’s commitment to blending industry excellence with engaging, memorable experiences.
Adding to the excitement, models and influencers brought energy and style the booth, ensuring that Tradeview was a trending topic throughout the summit. From product demonstrations to interactive sessions, the buzz surrounding Tradeview Markets was electric.
A Bright Future for Tradeview Markets
“Tradeview Markets is thrilled to have been such a pivotal part of the Finance Magnates London Summit 2024,” said Tim Furey, CEO at Tradeview Markets. “This event provided an incredible platform for us to connect with the global financial community, showcase our innovations, and highlight what makes Tradeview a leader in the industry. The response was phenomenal, and we’re excited to continue building on this momentum.”
Looking Ahead
Tradeview Markets remains dedicated to pushing boundaries and leading the way in the financial services sector. With the success of the Finance Magnates London Summit 2024, the company is poised for an exciting year ahead, filled with innovation, growth, and continued industry leadership. Additionally, Tradeview Markets will participate in the Traders Fair in Hong Kong on December 14th.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
China-Europe Industrial Innovation Zone: Creating a model zone for China-EU cooperation
2024 marks the 21st anniversary of establishing a comprehensive strategic partnership between China and Europe, China-EU relations are showing good momentum of consolidation and development. China looks forward to the EU becoming a key partner in pursuing Chinese modernization, sharing opportunities in its vast market, institutional opening-up, and deepening international collaboration.
Wuxi, a core city in the Yangtze River Delta urban agglomeration, has attracted investments from European companies such as AstraZeneca, Bosch, and Siemens since China’s coastal opening up. The city has opened up China-Europe freight train services and direct cargo routes to Europe, fostering deepening economic and trade cooperation—Wuxi High-tech Zone, located in the hinterland of the Yangtze River Delta with convenient transportation links. Since becoming a national high-tech zone in 1992, it has incubated a robust ecosystem of technological innovation, housing numerous postdoctoral workstations, listed companies, and high-tech enterprises. Ranked 4th among China’s top 100 districts for high-quality development and 18th among 177 national high-tech zones, Wuxi High-tech Zone stands out as a beacon of growth.
In November 2023, the Wuxi China-Europe Industrial Innovation Zone was officially launched.
As an open window for China-Europe cooperation, the China-Europe Industrial Innovation Zone aims to promote high-level openness, serving as a platform for sharing opportunities globally, a bridge for deepening EU collaboration, and a forefront for innovation in China-Eu partnerships. By the end of 2023, EU countries states had invested in 166 projects in the Wuxi High-tech Zone, with a total investment of €15 billion. In 2023 alone, these projects generated sales revenue of RMB 118.23 billion and contributed RMB 8.18 billion in taxes.
Spanning a total planned area of 24.5 square kilometers, the China-Europe Industrial Innovation Zone is situated in the Meicun area of the Wuxi High-tech Zone. The core area covers 7.7 square kilometers, with the initial development area along both sides of Xinhua Road spanning 1.15 square kilometers. Anchored in Meicun Street, the zone aims to become a model for China-Europe cooperation, providing a premium platform for the Wuxi High-tech Zone and the city of Wuxi to strengthen international collaboration. The first phase of construction has already reached the structural topping-off stage and is expected to be completed by March 2025.
Building on Wuxi High-tech Zone’s solid foundation of international industrial cooperation, the China-Europe Industrial Innovation Zone adheres to a philosophy of integrated development of science, industry, and urbanization. It is actively developing four international cooperation sub-parks: the China-Germany International Cooperation Industrial Park, the China-France International Cooperation Industrial Park, the China-Switzerland International Cooperation Industrial Park, and the China-Israel International Cooperation Industrial Park.
The China-Europe Industrial Innovation Zone targets an annual output value of RMB 160 billion and tax revenue exceeding RMB 8 billion. It aims to attract at least 30 European “hidden champion” enterprises, including over 10 multinational company headquarters. The zone will construct more than 500,000 square meters of innovation facilities and jointly establish at least three European industrial technology transfer centers. Efforts to attract major China-Europe cooperative projects are being intensified, with key EU-related projects such as Legrand, AML Systems, Schneider Electric, Faurecia, and Siemens accelerating their presence in the zone. The future focus will be on cutting-edge EU technologies and innovations, optimizing industrial structure and layout to position the zone as a leading provincial-level economic development zone, Wuxi High-tech Zone’s preferred industrial destination, and a top-tier international industrial cooperation zone renowned across China and the Yangtze River Delta.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
AIA Labs Introduces AIA Chain: A Game-Changing Blockchain for Financial Transactions
Tradeview Markets Shines at Finance Magnates London Summit 2024
China-Europe Industrial Innovation Zone: Creating a model zone for China-EU cooperation
Absolutely Princess: A New Children’s Classic by Mayra L Santana Warms Hearts Post Launch
Unusual Machines CEO Discusses Growth and Strategic Plans Post-IPO
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
-
Press Release5 days ago
A Omega Fencing Company Launches New Eco-Friendly Fencing Options for Environmentally Conscious Homeowners
-
Press Release7 days ago
The Strategy for Avoiding Failures for High Performers with Leila Entezam’s ‘SET UP’ Method
-
Press Release5 days ago
Humera Tamboli elevates sustainable fashion with purpose: Embracing Supima cotton and Beechwood to create skin friendly capsule clothing
-
Press Release1 day ago
Saba Launches Saba PURE Colostrum and Biotin Complex™: A New Era in Foundational Wellness
-
Press Release7 days ago
Aven Osborne Launches New Personal Website to Inspire and Connect Through Athletics, Academics, and Service
-
Press Release4 days ago
Knowledge Is Power: Minority Class Registers With State
-
Press Release4 days ago
Shop Better, Save Big: BetterFinds.com.au Unveils Black Friday Deals
-
Press Release4 days ago
QuickBooks SuperCondense reduces file size more drastically than standard condensing, resulting in faster load times and smoother navigation